Insider Trading February 10, 2026

Woodward Director Disposes of $1.96M in Stock After Option Exercise

Eileen P. Paterson sells 5,200 shares and exercises options the same day as Woodward posts stronger-than-expected Q1 fiscal 2026 results

By Priya Menon WWD
Woodward Director Disposes of $1.96M in Stock After Option Exercise
WWD

Woodward director Eileen P. Paterson sold 5,200 shares of the company on February 5, 2026, for roughly $1.96 million and exercised options to acquire the same number of shares at $79.81. The moves coincided with the company reporting fiscal 2026 first-quarter earnings and revenues that surpassed analyst forecasts, and with shareholder approval of three director elections.

Key Points

  • Director Eileen P. Paterson sold 5,200 Woodward shares on February 5, 2026, for about $1.96 million at prices between $377.93 and $378.31.
  • Paterson exercised options for 5,200 shares at $79.81 the same day, recorded with a total value of 415012; her direct holdings after these moves are 2,538 shares.
  • Woodward reported Q1 fiscal 2026 EPS of $2.17 and revenue of $996 million, both above the cited expectations; UBS raised its price target to $417 and maintained a Buy rating.
  • Sectors impacted include industrials and machinery markets, with potential implications for suppliers and investors focused on capital goods and aerospace-related equipment.

Director Eileen P. Paterson of Woodward, Inc. (NASDAQ: WWD) executed a sale of 5,200 shares of company stock on February 5, 2026, generating approximately $1.96 million in proceeds. The sales were completed at prices ranging from $377.93 to $378.31 per share.

On that same date Paterson exercised options to acquire 5,200 shares of Woodward common stock at an exercise price of $79.81 per share, for a stated aggregate value of 415012. After these transactions were recorded, Paterson's direct ownership in Woodward stood at 2,538 shares.

Separately, Woodward released first-quarter fiscal 2026 results that exceeded market expectations. The company reported earnings per share of $2.17, versus a consensus forecast of $1.66. Revenue for the quarter reached $996 million, topping the anticipated $890.37 million.

Following the quarterly report, UBS raised its price target for Woodward to $417 while maintaining a Buy rating, even as the company conveyed a conservative outlook for the approaching quarters. In corporate governance developments, Woodward shareholders approved the election of three directors to the board: David Hess, Mary Petryszyn, and Tana Utley, each to serve a three-year term.


Context and notable items

  • Paterson's sale of 5,200 shares produced about $1.96 million, with execution prices between $377.93 and $378.31.
  • That same day she exercised options to acquire 5,200 shares at $79.81, listed with a total value of 415012.
  • Post-transaction, Paterson directly holds 2,538 shares of Woodward common stock.
  • Woodward reported Q1 fiscal 2026 EPS of $2.17 and revenue of $996 million, both above the referenced expectations.
  • UBS increased its price target to $417 and kept a Buy rating while the company signaled a conservative near-term outlook.
  • Shareholders elected David Hess, Mary Petryszyn, and Tana Utley to three-year terms on the board.

The details above are drawn from company-reported filings and public disclosures on the transactions and quarterly results.

Risks

  • The company provided a conservative outlook for upcoming quarters, creating uncertainty about near-term performance and revenue trajectories in the industrials sector.
  • Paterson's sale reduced her direct shareholding to 2,538 shares, a change in insider ownership that may prompt investor scrutiny of insider liquidity or portfolio rebalancing.
  • Although UBS raised its price target and maintained a Buy rating, forward expectations remain contingent on Woodward meeting or exceeding its own conservative guidance.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026